Apmonia Therapeutics

#ReimsVisionR 🚀 Installée à #Reims depuis 2019, Apmonia Therapeutics vient de lancer une levée de fonds de 20 millions € 💰 Dans le but de financer les premiers essais cliniques de son candidat-médicament phare qui s'attaque aux tumeurs, la #biotech rémoise Apmonia Therapeutics vise 20 millions €. 🔝 Nommé TAX2, son candidat-médicament s'appuie notamment sur l'#immunothérapie pour détruire les tumeurs cancéreuses. 🤝 Grâce à un écosystème dynamique et des partenaires sur le territoire tels que l'Université de Reims Champagne-Ardenne ou INNOVACT, incubateur de startups à Reims , Apmonia Therapeutics se développe depuis Reims et emploie aujourd'hui une quinzaine de salariés, la société prévoit de renforcer son effectif de 30 à 40 personnes d'ici à trois ans. 🔬L'industrie pharmaceutique et la #santé font partie des domaines clés du développement #économique du #GrandReims. Le développement et la réussite d'entreprises comme Apmonia Therapeutics positionnent le territoire comme terre d'#innovation, de #Recherche & #Développement ! #oncologie #technologie #ReimsExemplR Lire l'article dans Les Echos https://lnkd.in/e7Duzk-P Albin JEANNE | Communauté urbaine du Grand Reims | Ville de Reims | Quest for change - Quest for health | Région Grand Est | Bpifrance | Grand E-Nov+, l'Agence régionale des transformations | Invest Eastern France | POLEPHARMA | France Biotech | France BioLead | Secrétariat général pour l'investissement | La French Tech Est | Capital Grand Est | Finovam Gestion | CNRS | Gustave Roussy | BioValley France | Medicen Paris Region | MATWIN | Paris Saclay Cancer Cluster (PSCC)

💻 IN THE PRESS TODAY ! 🗞️ In today's issue of Les Echos, we highlight our cancer therapy development activities. In the midst of a wealth of news, we talk about upcoming clinical trials, immunotherapy, our discovery activities (superb illustration by Mariem Ghoula!), Apmonia Therapeutics' recent success at European Innovation Council and SMEs Executive Agency (EISMEA) #EICaccelerator, and the fund-raising underway with the aim of closing a €20m euro Series A round to support company's scale-up. Thanks to Juliette Poulain for putting the spotlight on us! ➡️ Link to the full article [in French]: https://lnkd.in/e7Duzk-P

📺 Ravi d'intervenir mardi 15 octobre à 18h00 dans l'émission "100% HealthTech, le live de France Biotech" aux côtés de Benjamin Garel pour évoquer l'actualité d'Apmonia Therapeutics et les synergies avec le Paris Saclay Cancer Cluster (PSCC). Inscriptions 👉 https://lnkd.in/eCH_xgUp

🔴 En direct des Sélections Régionales France Catapult 2024 chez notre partenaire Cap Digital ! Cancérologie, médecine régénérative, immunologie… 10 startups innovantes et prometteuses, en quête de financement, sont en compétition pour décrocher leur place aux demi-finales européennes. Dans la catégorie Life Sciences : - Apmonia Therapeutics, par Albin JEANNE - ByoRNA, par Pascal Viguié - ErVimmune, par Nathalie Donne - Nūmi, par Eugénie Pezé-Heidsieck, PhD - PepKon, par Jonathan Levy Dans la catégorie HealthTech : - Healshape, par Sophie Brac de la Perrière - Hopia, par Victoire Bach - Lifebloom, par Damien Roche - Scienta Lab, par Vincent Bouget - THE ELEMENT Biotechnology, par Awatef BEN TAHAR Au programme : 10 minutes de pitch et 5 minutes de questions devant un jury d’investisseurs et d'experts de la santé, comprenant : Sofia Arnal, associée - AdBio partners Sophie PIERRIN LEPINARD, Directrice de Participations Sciences de la Vie - BNP Paribas Développement Sandra Kanani, PhD MBA, Présidente - Anahita Consulting healthcare Antoine Michel, investisseur social et green - Investir&+ Nicolas Doulet, Head Of Business Development - Home Biosciences. Les demi-finalistes seront bientôt dévoilés après délibération du comité de sélection ! Julia Morawski #Healthcare #Catapult

I'm honored to be included in the Institut Choiseul list ‘The 40 who embody innovation in healthcare’, which gives an overview of the driving forces that are changing the face of healthcare through the prism of innovation and resilience. This is recognition of the impact of Apmonia Therapeutics and the day-to-day commitment of its outstanding team, but it is also an opportunity to reiterate the importance of innovation in building a sustainable and humane healthcare system! Read the full article on Maddyness 👉 https://lnkd.in/eSMUswqj #ChoiseulTop40Santé #biotechnology #fightcancer

⭐ Matrix Biology Europe (MBE) conference is a blast ! ⭐ #MBE2024 is THE international stage for exchanging ideas at the cutting edge of innovation in the field of #extracellularmatrix research, bringing together leading scientists from academia, medicine, and industry. The ECM Targeting & Signaling in Homeostasis & Cancer session took place today, co-chaired by Johanna Englund & Ulrich VALCOURT, including insightful talks from Alexandra Naba, Ph.D. (founder of the #MatrisomeProject), Ellen Van Obberghen-Schilling, Konstantinos Papadakos, and an update on Apmonia Therapeutics recent advances by CEO Albin JEANNE. Two more days of exchanges and emulation with the #ECM community to accelerate discoveries in the field, and catalyse collaborations. Come and reach out to our team Mariem Ghoula Marion Etiennot Stephane Dedieu !

Matrix Biology Europe (MBE) 2024 conference is just around the corner! MBE conference is the main European scientific event for the #extracellularmatrix research community, bringing together 400-500 scientists from all over the world. Come and meet our team Marion Etiennot Mariem Ghoula Stephane Dedieu Albin JEANNE ! 📍Lyon, France 📆 24-27 September 2024 Apmonia Therapeutics scientists will present an update on the company's research work during the "ECM Biosynthesis, Dynamics and Epigenetics" and "ECM Targeting and Signaling in Homeostasis and Cancer" sessions (more details below).

🏆 Apmonia Therapeutics is particularly proud to have received the prestigious i-Nov award from Bruno Bonnell / Secretary general for investment last night during the #Innovation Awards ceremony held in Cité de la musique, Paris. 🏅Winner if the 11th edition of the i-Nov innovation contest, Apmonia Therapeutics received the largest amount of funding (€2.2M) among the prizewinners, which underlines the disruptive nature of our innovation against cancer, and rewards the work and dedication of our teams. 👏 Congratulations to the other winners of the i-Lab and i-Nov competitions, with whom we had the opportunity to exchange views during a full day dedicated to innovation, among which Lys Therapeutics Manuel BLANC Philippe Dujardin VG2D Pharma Imane Wild CARLA Biotherapeutics Maxime FREDON Thanks to the Gouvernement, ADEME and Bpifrance for their trust and support via #France2030 ! Ministère de l'Enseignement supérieur et de la Recherche ministere economie Ministère de la Santé Direction Générale des Entreprises Direction générale de la recherche et de l'innovation (DGRI) Lise ALTER Lucie Mondoulet Paris Saclay Cancer Cluster (PSCC)

Insightful discussion about investment in #deeptech start-ups and innovative SMEs between our CEO Albin JEANNE and entrepreneurial leaders from dynamic companies such as Latitude and VitiBot. The involvement of influential figures such as French Député Paul Midy, investor Olivier de Panafieu from AUDACIA and Director of La French Tech Est underlines that the values of innovation and collaboration supported by Apmonia Therapeutics are essential to driving technological progress and national economic growth. Whether we're #SpaceTech 🚀 or #BioTech 🧬 pioneers, let's keep pushing back the frontiers of innovation! #FightCancer #FrenchTech #Industrialisation #Innovation Communauté urbaine du Grand Reims

🔥 HOT OFF THE PRESS ! 🔥 We are pleased to announce publication of a paper highlighting the relevance of targeting TSP-1/CD47 axis in ovarian cancer and testing Apmonia Therapeutics TAX2 peptide in the journal BMC Molecular Cancer (5-year Impact Factor: 31.3). This work is a great achievement by our team and the fruit of an exemplary collaboration between leading laboratories and hospitals (including long-standing partners at CNRS MEDyC and Gustave Roussy), and is a further step in advancing research in the field of ovarian cancer therapies. Link to publication below (open access). #TAX2 #extracellularmatrix #tumormicroenvironment #ovariancancer